

CURRICULUM VITAE

Date: October 25, 2011

NAME

Mark K Buyyounouski, MD, MS

TITLE

Associate Professor
Director, Clinical Research

OFFICE ADDRESS

Department of Radiation Oncology
Fox Chase Cancer Center
333 Cottman Avenue
Philadelphia, PA, 19111
Phone: 215-214-3707
Fax: 215-214-1629
E-mail: mark.buyyounouski@fccc.edu
www.fccc.edu/physician_directory/radiation/buyyounouski.html

EDUCATION

<u>Dates</u>	<u>Discipline</u>	<u>Degree</u>	<u>Institution</u>
8/1991 - 5/1995	Physics	Bachelor of Science	Lafayette College, Easton, PA
8/1995 - 6/1996	Medical Physics	Master of Science	School of Engineering and Applied Science, Columbia University, New York, NY
8/1996 - 5/2000	Medicine	Doctor of Medicine	New Jersey Medical School, University of Medicine and Dentistry of New Jersey, Newark, NJ

POST-DOCTORAL TRAINING

<u>Dates</u>	<u>Speciality</u>	<u>Title</u>	<u>Hospital</u>
7/2000 - 6/2001	Medicine	Intern	Saint Barnabas Medical Center, Livingston, NJ
7/2001 - 6/2005	Radiation Oncology	Resident	Fox Chase Cancer Center, Philadelphia, PA

LICENSURE

<u>Date(s)</u>	<u>Type of Licensure</u>
8/1998	United States Medical Licensing Exam (USMLE) Step I
3/2000	USMLE Step II
7/2002	USMLE Step III
4/2003 – Present	Medical License, State of Pennsylvania

CERTIFICATION

<u>Dates</u>	<u>Type of Certification</u>
6/2006 – Present	American Board of Radiology (Therapeutic)

ACADEMIC APPOINTMENTS

<u>Dates</u>	<u>Title</u>	<u>Department</u>	<u>Institution</u>
7/2005 – 6/2011	Assistant Professor	Radiation Oncology	Fox Chase Cancer Center, Philadelphia, PA
6/2011 – Present	Associate Professor	Radiation Oncology	Fox Chase Cancer Center, Philadelphia, PA

HOSPITAL APPOINTMENTS

<u>Dates</u>	<u>Title</u>	<u>Hospital</u>
7/2005 – Present	Attending Physician	Fox Chase Cancer Center, Philadelphia, PA
7/2005 – Present	Consulting Staff	Jeans Hospital, Philadelphia, PA
7/2005 – 7/2009	Clinic Physician, Prostate Cancer Risk Assessment Program	Fox Chase Cancer Center, Philadelphia, PA
1/2009 – Present	Director, Clinical Research	Fox Chase Cancer Center, Philadelphia, PA

HONORS AND DISTINCTIONS

<u>Year</u>	<u>Name of Award</u>
1993	EXCEL Research Scholarship, Department of Physics, Lafayette College
2003	Resident/Fellow Research Award, Radiological Society of North America Roentgen
2005	Resident/Fellow Research Award, Radiological Society of North America Roentgen
2005	American Society for Radiation Oncology Travel Grant to attend National Cancer Institute Radiation Research Program/Radiation Oncology Sciences Program Young Investigators Workshop for Radiation Oncology
2008	Radiological Society of North America Roentgen Seed Grant

VISITING PROFESSOR

	<u>Year</u>
Karmanos Cancer Institute, Wayne State University, Detroit, Michigan	2011
Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah	2011

PROFESSIONAL SOCIETIES

American Society for Radiation Oncology (ASTRO)
 Radiological Society of North America (RSNA)
 American Radium Society (ARS)
 American Brachytherapy Society (ABS)
 American Medical Association (AMA)

MAJOR PROFESSIONAL SERVICE

<i>National Service</i>	<u>Year(s)</u>
Member , Emerging Technologies Committee, Health Policy Council, ASTRO	2007 - Present
Member , Evaluation Subcommittee, Emerging Technologies Committee, Health Policy Council, ASTRO	2007 - 2011
Task Group Leader , Evaluation Subcommittee, Emerging Technologies Steering Committee, ASTRO	2007 - 2009
Co-Chair , Evaluation Subcommittee, Emerging Technologies Committee, ASTRO	2009 - 2011
Member , Genitourinary Cancer Resource Panel, ASTRO	2009 - Present
Reviewer , ASTRO abstract	2010, 2011
Member , Genitourinary Steering Committee, Radiation Therapy Oncology Group (RTOG)	2007 - Present
Member-at-Large , Executive Committee, RTOG	2011 - 2015
Co-Chair , Prostate Brachytherapy School, ABS	2010, 2012
Secretary , Board of Directors, ABS	2010 - 2011
Treasurer , Board of Directors, ABS	2011 - 2013
Reviewer , ABS Abstracts	2010
Member , Scientific Program Committee, ARS	2010 - 2011
Member , ASCO/ASTRO/SUO GU Cancers Symposium Program Committee	2011 - 2014
Member , National Comprehensive Cancer Network (NCCN) Testicular/Kidney Cancer Committee	2010 - Present
Oral Board Examiner (Genitourinary Cancer), American Board of Radiology	2009, 2010

(ABR), Radiation Oncology In-training Exam Author (Genitourinary Cancer), American College of Radiology (ACR), Radiation Oncology Member , ABR GU Category Committee for Written and Oral Exams	2010, 2011 2012
<i>International Service</i>	<u>Year(s)</u>
Member , Independent Data Monitoring Committee, MacCallum Cancer Centre, Melbourne, Australia. Radiotherapy – Adjuvant vs Early Salvage (RAVES): A phase III multi-centre randomised trial comparing adjuvant radiotherapy with early salvage RT in patients with positive margin(s) or extraprostatic disease following radical prostatectomy	2008 - Present
<i>Journal/Editorial Activity</i>	<u>Year(s)</u>
Associate Senior Editor , International Journal of Radiation Oncology, Biology, and Physics	2011
<i>Other Public Service</i>	<u>Year(s)</u>
Community Outreach, Prostate Cancer Screening, Philadelphia, PA Lecture on IMRT for Prostate Cancer, 10th Annual Prostate Cancer Conference of the American Cancer Society, Pennsylvania Division	2002 – Present 2005

INSTITUTIONAL AND DEPARTMENT SERVICE

<i>Fox Chase Service</i>	<u>Year(s)</u>
Information Technology Physician Advisory Committee (ITPAC)	2007 – Present
Fox Chase Cancer Center Partners, Quality Assurance/Quality Improvement	2008 – Present
Reviewer for Radiation Oncology	
Full Member Principal Investigator, Radiation Therapy Oncology Group	2009 – Present
Executive Committee on Reseach (ECOR)	2009
Population Studies Facility Advisory Committe (PSF FAC)	2009 – Present
Research Review Committee (RRC)	2009 – Present
American Cancer Society-Institutional Research Grants Review Committee	2010
Fox Chase Data Safety Monitoring Board (DSMB)	2011 - Present
Faculty and Staff Library Advisory Committee	2011 - Present

PEER REVIEW

<i>Journals</i>	<u>Role</u>
Journal of Clinical Oncology	Ad hoc Reviewer
International Journal Radiation Oncology • Biology • Physics	Ad hoc Reviewer
Cancer	Ad hoc Reviewer
Journal of Urology	Ad hoc Reviewer
Urology	Ad hoc Reviewer
The Cancer Journal	Ad hoc Reviewer
Nature Clinical Practice Urology	Ad hoc Reviewer
Brachytherapy	Ad hoc Reviewer
Clinical Advances in Hematology & Oncology	Ad hoc Reviewer
British Journal of Urology International	Ad hoc Reviewer
Prostate Cancer and Prostate Diseases	Ad hoc Reviewer
Pratical Radiation Oncology	Ad hoc Reviewer

<i>Governmental Agency</i>	<u>Role</u>
-----------------------------------	-------------

U.S. Department of Health and Human Services, Agency for Healthcare Research and Quality Peer Review

National Medical Research Council, Singapore, China Grant Review

United Kingdom Radiation Oncology, National Working Group for Stereotactic Body Radiotherapy, Stereotactic Body Radiotherapy in Prostate Cancer: Review and Guidelines Peer Review

MAJOR PROFESSIONAL INTERESTS

Genitourinary cancer
 Definitive and salvage prostate brachytherapy
 Intensity modulated and image guided radiotherapy
 Translational applications of magnetic resonance imaging for the detection and treatment of prostate cancer

CLINICAL TRIALS

<u>Years</u>	<u>Institution</u>	<u>PI/Co-PI</u>	<u>Title</u>
2003 – Present	Fox Chase Cancer Center	Co-PI	Outcomes Following Intensity Modulated Radiation Therapy With and Without Erectile Tissue Dose Sparing For Favorable To Intermediate Prostate Cancer.

RESEARCH SUPPORT

Past Funding

<u>Date</u>	<u>Funding Source</u>	<u>PI/Co-PI</u>	<u>Title</u>
2008 - 2010	RSNA	PI	Early Detection of Locally Persistent Prostate Cancer

Current Funding

<u>Date</u>	<u>Funding Source</u>	<u>PI/Co-PI</u>	<u>Title</u>
2009 - Present	University of Miami/Sylvester Pap Corps	Co-PI	Genetic and Dosimetric Determinants of Toxicity in Men Treated With Radiotherapy for Prostate Cancer
2011 - Present	Varian	PI	Clinical/Biochemical Outcomes Of Patients With Non-Metastatic Prostate Cancer Treated With Definitive Radiation Or Surgery

TEACHING EXPERIENCE

Local Teaching

<u>Years</u>	<u>Role</u>	<u>Course</u>
2005 – Present	Lecturer	Seminoma (Annual Resident and Fellow Clinical Lecture Program, Department of Radiation Oncology, Fox Chase Cancer Center)
2008 – Present	Lecturer	Prostate Cancer (Annual Resident and Fellow Clinical Lecture Program, Department of Radiation Oncology, Fox Chase Cancer Center)
2008 – Present	Lecturer	Prostate Radiotherapy and Erectile Dysfunction (Annual Resident and Fellow Clinical Lecture Program, Department of Radiation Oncology, Fox Chase Cancer Center)

Continuing Medical Education

<u>Year</u>	<u>Role</u>	<u>Course</u>
2006	Faculty	Prostate Seed Implants: Comparison of External Beam and Radical Prostatectomy, CME Program at 15th Annual Radiation Oncology Conference for Nurses, Therapists and Dosimetrists, Philadelphia, PA.

2007	Faculty	Hypofractionation, CME Program at 16th Annual Radiation Oncology Conference for Nurses, Therapists and Dosimetrists, Philadelphia, PA.
2008	Faculty	Prostate MRI and Spectroscopy, American Brachytherapy Society School of Prostate Brachytherapy, Chicago, IL.
2008	Faculty	Prostate Radiotherapy and Erectile Dysfunction, American Brachytherapy Society School of Prostate Brachytherapy, Chicago, IL.
2009	Faculty	Prostate MRI, Spectroscopy and Other Advanced Techniques, CME Program at 18th Annual Radiation Oncology Conference for Nurses, Therapists and Dosimetrists, Philadelphia, PA.
2009	Faculty	Stereotactic Body Radiotherapy for Prostate Cancer, Second Annual International Symposium on Stereotactic Body Radiation Therapy and Stereotactic Radiosurgery, Lake Buena Vista, FL.
2009	Faculty	Management of Localized Prostate Cancer, 8th Annual Mid Atlantic Oncology Update, Sheraton Inner Harbor Hotel, Baltimore, MD.
2009	Faculty	Treatment Planning for Prostate Cancer: Imaging (US CT MR) Immobilization, Fields, Tumor and Normal Tissue Doses, 51st Annual Meeting of the American Society for Radiation Oncology (ASTRO), Chicago, IL.
2009	Faculty	Post-operative Radiotherapy for Prostate Cancer. Fox Chase Cancer Center Urologic Conference, Philadelphia, PA.
2010	Faculty	Treatment Planning for Prostate Cancer: Imaging (US CT MR) Immobilization, Fields, Tumor and Normal Tissue Doses, 52st Annual Meeting of the American Society for Radiation Oncology (ASTRO), San Diego, CA.
2010	Moderator	GU Poster Discussion, 52st Annual Meeting of the American Society for Radiation Oncology (ASTRO), San Diego, CA.
2010	Faculty	Secondary Malignancies Following Prostate Radiation: Is the data conclusive? American Brachytherapy Society School of Prostate Brachytherapy, Chicago, IL.
2010	Moderator	Physics and Dose-Escalation, American Brachytherapy Society School of Prostate Brachytherapy, Chicago, IL.
2010	Faculty	Erectile Dysfunction and Radiation for Prostate Cancer. American Brachytherapy Society School of Prostate Brachytherapy, Chicago, IL.
2010	Faculty	Stereotactic Body Radiotherapy for Prostate Cancer. Advance in Stereotactic Radiotherapy, Furlong, PA.
2010	Faculty	Prostate Cancer Anatomy and Contouring, Prostate BOOST Course, Annual Meeting of the Radiologic Society of North America, Chicago, IL.
2011	Discussant	Initial Report of RTOG 9601: A Phase III Trial in Prostate Cancer: Anti-androgen Therapy (AAT) with Bicalutamide during and after Radiation Therapy (RT) Improves Freedom from Progression and Reduces the Incidence of Metastatic Disease in Patients following Radical Prostatectomy (RP) with pT2-3, N0 Disease, and Elevated PSA Levels, Semi-Annual Meeting of Radiation Therapy Oncology Group (RTOG), San Diego, CA.
2011	Moderator	Poster Discussion: Prostate, Annual Meeting of the American Brachytherapy Society, San Diego, CA.

2011	Lecturer	An Update of Post-Prostatectomy Radiotherapy for Prostate Cancer, Barbara Ann Karmanos Cancer Institute, Wayne State University, Detroit, MI.
2011	Moderator	Scientific Session, GI/GU Cancers, 93rd Annual Meeting of the American Radium Society, May 1-4, 2011, Palm Beach, Florida.
2011	Lecturer	Current Concepts in Post-Prostatectomy Radiotherapy for Prostate Cancer, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT.
2011	Faculty	Treatment Planning for Prostate Cancer: Imaging (US CT MR) Immobilization, Fields, Tumor and Normal Tissue Doses, 53rd Annual Meeting of the American Society for Radiation Oncology (ASTRO), Miami, FL.
2011	Faculty	Androgen Suppression and Prostate Cancer: Is the Treatment Worse than the Disease, 53rd Annual Meeting of the American Society for Radiation Oncology (ASTRO), Miami, FL.
2011	Faculty	Prostate Cancer Anatomy and Contouring, Prostate BOOST Course, Annual Meeting of the Radiologic Society of North America, Chicago, IL.

Self Assessment Module

<u>Year</u>	<u>Role</u>	<u>Course</u>
2010	Faculty	Treatment Planning for Prostate Cancer: Imaging (US CT MR) Immobilization, Fields, Tumor and Normal Tissue Doses

Other Invited Presentations

<u>Year</u>	<u>Role</u>	<u>Title</u>
2004	Lecturer	Erectile Tissue Sparing Intensity Modulated Radiation Therapy for Prostate Cancer, Saint Barnabas Medical Center, Livingston, NJ.
2008	Lecturer	Prostate Biopsy Information and Magnetic Resonance Imaging: A Rationale for Novel Radiotherapy Approaches, Cleveland Clinic, Cleveland, OH.
2009	Lecturer	Prostate Localization and Motion in External Beam Radiotherapy for Prostate Cancer, Philadelphia Roentgen Society, Philadelphia, PA.
2010	Panelist	Cancer Conference, Virtua Memorial Hospital Burlington County, NJ.

BIBLIOGRAPHY (* denotes senior correspondent author or resident or fellow)

Peer-Reviewed Paper

1. Zaorsky NG, **Buyyounouski MK***, Li T, Horwitz EM. Aspirin Use Reduces The Risk Of Biochemical Recurrence Following Prostate Radiotherapy. (In Revision, IJROBP)
2. Lawrence YR, Paulus R, Langer C, Werner-Wasik M, **Buyyounouski MK**, Komaki R, Machtay M, Smith C, Axelrod RS, Wasserman T, Byhardt R, Movsas B. Carboplatin and paclitaxel based chemoradiation in locally advanced non-small cell lung cancer: a long-term follow-up of Radiation Therapy Oncology Group (RTOG) 9801. (In Review, Journal of Thoracic Oncology)
3. Klayton T, Price R, **Buyyounouski MK**, Sobczak M, Greenberg R, Li J, Keller L, Sopka D, Kutikov A, Horwitz E. Prostate Bed Motion During Intensity Modulated Radiotherapy Treatment. (In Revision, IJROBP)

4. **Buyyounouski MK**, Pickles T, Kestin L, Allison R, Williams SG. Validating The Interval To Biochemical Failure For The Identification Of Potentially Lethal Prostate Cancer. (In Revision, JCO)
5. D'Ambrosio DJ, Bayouth J, Chetty IJ, **Buyyounouski MK**, Price RA, Correa CR, Dilling TJ, Franklin GE, Xia P, Harris EER, Konski A. Continuous Localization Technologies for Radiotherapy Delivery: Report of the ASTRO Emerging Technology Committee. (Accepted, Practical Radiation Oncology)
6. Turaka A, Parsons B, **Buyyounouski MK**. Radiotherapy for the Pituitary Metastasis: Report of Four Cases. (In Press, Tumori)
7. Feigenberg SJ, Sharma N, Yu JQ, Wang L, **Buyyounouski MK**, Unger M, Borghaei H, King E, Scott W, Callahan E, Movsas B. A Phase I Radiation Dose Escalation of Stereotactic Body Radiotherapy for Malignant Lung Tumors. (In Press, Journal of Biomedical Science and Engineering).
8. Turaka A, **Buyyounouski MK***, Hanlon AL, Horwitz EM, Greenberg RE, Movsas B. Hypoxic Prostate/Muscle pO₂ Ratio Predicts for Outcome in Patients with Localized Prostate Cancer: Long-term Results. Int J Radiat Oncol Biol Phys. 2011 Oct 8. [Epub ahead of print]
9. Hossain M, Schirmer T, Richardson T, Chen L, **Buyyounouski MK**, Ma C. Effect Of Gold Marker Seeds On Mr Spectroscopy Of The Prostate. (In Press, IJROBP)
10. Klayton TL, Ruth K, **Buyyounouski MK**, Uzzo RG, Wong YN, Chen DYT, Sobczak M, Peter R, Horwitz EM. Prostate-specific antigen doubling time predicts the development of distant metastases for patients who fail 3-dimensional conformal radiotherapy or intensity modulated radiation therapy using the Phoenix definition. Practical Radiation Oncology. 2010 Oct; 1(4):235-242.
11. Klayton TL, Ruth K, Horwitz EM, Uzzo RG, Kutikov A, Chen DYT, Sobczak M, **Buyyounouski MK***. Young Age Under 60 Years Is Not A Contraindication To Treatment With Definitive Dose Escalated Radiotherapy For Prostate Cancer. Radiother Oncol. 2011 Aug 31. [Epub ahead of print]
12. Pahlajani N, Ruth KJ, **Buyyounouski MK**, Chen DY, Horwitz EM, Hanks GE, Price RA, Pollack A. Radiotherapy Doses of 80 Gy and Higher are Associated with Lower Mortality in Men with Gleason Score 8 to 10 Prostate Cancer. Int J Radiat Oncol Biol Phys. 2011 Jul 13. [Epub ahead of print]
13. Lubbe W, Cohen R, Sharma N, Ruth K, Peters R, Li J, **Buyyounouski M**, Kutikov A, Chen D, Uzzo R, Horwitz E. Biochemical and clinical experience with real-time intraoperatively planned permanent prostate brachytherapy. Brachytherapy. 2011 Jul 2. [Epub ahead of print]
14. Canter D, Greenberg RE, Horwitz EM, Kutikov A, Li J, Long C, **Buyyounouski M**, Boorjian SA. Implantation of electromagnetic transponders following radical prostatectomy for delivery of IMRT. Can J Urol. 2010 Oct;17(5):5365-9.
15. Williams S, **Buyyounouski M**, Kestin L, Duchesne G, Pickles T. Predictors of Androgen Deprivation Therapy Efficacy Combined with Prostatic Irradiation: The Central Role of Tumor Stage and Radiation Dose. Int J Radiat Oncol Biol Phys. 2011 Mar 1;79(3):724-31. Epub 2010 May 14.
16. Boorjian SA, Karnes RJ, Viterbo R, Rangel LJ, Bergstralh EJ, Horwitz EM, Blute ML, **Buyyounouski MK**. Long-term Survival After Surgery Versus External Beam Radiotherapy With and Without Androgen Deprivation for High-Risk Prostate Cancer. Cancer. 2011 Jul 1;117(13):2883-91. Epub 2011 Jan 10.
17. **Buyyounouski MK**, Price R, Balter P, Dilling T, D'Ambrosio D, Miller R, Schefter T, Lewis B. Stereotactic Body Radiotherapy for Lung Cancer. A report of Report of the American Society for Therapeutic Radiology and Oncology (ASTRO) Emerging Technology Committee (ETC). Int J Radiat Oncol Biol Phys. 2010 Sep 1;78(1):3-10. Epub 2010 Jul 17.
18. **Buyyounouski MK**, Price RA Jr, Harris EE, Miller R, Tomé W, Schefter T, Parsai EI, Konski AA, Wallner PE. Stereotactic body radiotherapy for primary management of early-stage, low- to intermediate-risk prostate cancer: report of the American Society for Therapeutic Radiology and Oncology Emerging Technology Committee. Int J Radiat Oncol Biol Phys. 2010 Sep 1;78(1):3-10. Epub 2010 Jul 17.

19. Sharma NK, Li T, Chen DYT, Pollack A, Horwitz EM, **Buyyounouski MK***. Intensity Modulated Radiation Therapy Reduces Gastrointestinal Morbidity in Patients Treated with Androgen Deprivation Therapy for Prostate Cancer. *Int J Radiat Oncol Biol Phys*. 2011 Jun 1;80(2):437-44. Epub 2010 Nov 2.
20. Cohen RJ, Sharma NK, Yu JQ, Wang L, **Buyyounouski MK**, Unger M, Borghaei H, King E, Scott W, Callahan E, Movsas BJ, Feigenberg SJ. (2010) A Phase I Radiation Dose Escalation of Stereotactic Body Radiotherapy for Malignant Lung Tumors. *Journal of Biomedical Science and Engineering*. 2010; 3(4):351-358.
21. Turaka A, Parsons RB, **Buyyounouski MK***. Lung Cancer Presents As Addisonian Crisis Secondary To A Solitary Pituitary Metastasis. *Journal of Radiotherapy in Practice*. 2009 Dec; 8(4):229-232.
22. Sharma NK, Eade TN, **Buyyounouski MK**, Li J, McNeeley S, Crawford K, Chen DYT, Uzzo RG, Horwitz EM. An Intraoperative Real-Time Sleeved Seed Technique For Permanent Prostate Brachytherapy. *Brachytherapy*. 2010 Apr-Jun;9(2):126-30. Epub 2009 Oct 21.
23. Li JS, Jin L, Pollack A, Horwitz EM, **Buyyounouski MK**, Price RA, Ma C-M. Gains from Real-time Prostate Motion Tracking During External Beam Radiation Therapy. *Int J Radiat Oncol Biol Phys*. 2009 Dec 1;75(5):1613-20. Epub 2009 Oct 14.
24. Kaplan DJ, Boorjian SA, Ruth K, Egleston BL, Chen DYT, Viterbo R, Uzzo RG, **Buyyounouski MK**, Raysor S, Giri VN. Evaluation of the Prostate Cancer Prevention Trial Risk Calculator in a High-Risk Screening Population. *BJU Int*. 2010 Feb;105(3):334-7. Epub 2009 Aug 25.
25. Michalski JM, Lawton C, El Naqa I, Ritter M, O'Meara E, Seider MJ, Lee WR, Rosenthal SA, Pisansky T, Catton C, Valicenti RK, Zietman AL, Bosch WR, Sandler H, **Buyyounouski MK**, Ménard C. Development of RTOG Consensus Guidelines for the Definition of the Clinical Target Volume for Postoperative Conformal Radiation Therapy for Prostate Cancer. *Int J Radiat Oncol Biol Phys*. 2010 Feb 1;76(2):361-8. Epub 2009 Apr 23.
26. Giri VN, Egleston B, Ruth K, Uzzo RG, Chen DY, **Buyyounouski M**, Raysor S, Hooker S, Torres JB, Ramike T, Mastalski K, Kim TY, Kittles R. Race, Genetic West African Ancestry, and Prostate Cancer Prediction by Prostate-Specific Antigen in Prospectively Screened High-Risk Men. *Cancer Prev Res (Phila)*. 2009 Mar;2(3):244-50. Epub 2009 Feb 24.
27. Wang L, Hayes S, Paskalev K, Jin L, **Buyyounouski MK**, Ma CM, Feigenberg SJ. Dosimetric comparison of stereotactic body radiotherapy using 4D CT and multiphase CT images for treatment planning of lung cancer: evaluation of the impact on daily dose coverage. *Radiother Oncol*. 2009 Jun;91(3):314-24. Epub 2008 Dec 26.
28. Lawton C, Michalski J, El-Naqa I, **Buyyounouski MK**, Lee WR, Menard C, O'Meara, Rosenthal S, Ritter M, Seider M. RTOG GU Radiation Oncology Specialists Reach Consensus on Pelvic Lymph Node Volumes for High-Risk Prostate Cancer. *Int J Radiat Oncol Biol Phys*. 2009 Jun 1;74(2):383-7. Epub 2008 Oct 22.
29. D'Ambrosio DJ, Li T., Horwitz EM, Chen DY, Pollack A, **Buyyounouski MK***. Does Treatment Duration Affect Outcome Following Radiotherapy For Prostate Cancer? *Int J Radiat Oncol Biol Phys*. 2008 Dec 1;72(5):1402-7. Epub 2008 May 9.
30. Kaplan DJ, Crispin PL, Greenberg RE, Chen DYT, Viterbo R, **Buyyounouski MK**, Horwitz EM, Uzzo RG. Residual Prostate Cancer Following Radiotherapy: A Study of Radical Cystoprostatectomy Specimens. *Urology*. 2008 Sep;72(3):654-8. Epub 2008 Mar 4.
31. D'Ambrosio DJ, Ruth K, Horwitz E, Chen DJ, Pollack A, **Buyyounouski MK***. Does Transurethral Resection of Prostate (TURP) affect outcome in patients that subsequently develop prostate cancer? *Urology*. 2008 May;71(5):938-41. Epub 2008 Feb 15.
32. Eade TN, Ruth K, D'Ambrosio DJ, Feigenberg SJ, **Buyyounouski MK**, Uzzo RG, Pollack A and Horwitz EM. Comparison of Outcomes in Low Risk Prostate Cancer: I-125 Seed Brachytherapy vs. Intensity Modulated Radiotherapy. *Int J Radiat Oncol Biol Phys*. 2008 Jun 1;71(2):338-45. Epub 2008 Jan 22.
33. D'Ambrosio DJ, Ruth K, Horwitz EM, Uzzo RG, Pollack A, **Buyyounouski MK***. How Can Men Destined For

- Biochemical Failure After Androgen Deprivation And Radiotherapy Be Identified Earlier? *Int J Radiat Oncol Biol Phys.* 2008 Apr 1;70(5):1487-91. Epub 2007 Dec 31.
34. Abramowitz MC, Li T, **Buyyounouski MK**, Ross E, Uzzo RG, Pollack A, Horwitz EM. The Phoenix definition of biochemical failure predicts for overall survival in patients with prostate cancer. *Cancer.* 2008 Jan 1;112(1):55-60.
 35. Williams SG, **Buyyounouski MK**, Pickles T, Kestin L, Martinez A, Hanlon AL and Duchesne G. The role of the percentage of biopsy cores positive for malignancy in the prediction of prostate cancer radiotherapy outcome is limited: A multicentre analysis of 3264 patients. *Int J Radiat Oncol Biol Phys.* 2008 Mar 15;70(4):1169-75. Epub 2007 Oct 29.
 36. Giri V, Beebe-Dimmer J, **Buyyounouski M**, Chen D, Watkins Bruner D, Konski A, Feigenberg SJ, Uzzo RG, Raysor S, Mirchandani I, Gordon R, Cescon T, Godwin A, Weaver J, Hanks G. Prostate Cancer Risk Assessment Program – A Ten-Year Update of Cancer Detection. *J Urol.* 2007 Nov;178(5):1920-4; discussion 1924. Epub 2007 Sep 17.
 37. **Buyyounouski MK**, Hanlon AL, Horwitz EM, Pollack A. Interval To Biochemical Failure Is Highly Prognostic For Distant Metastasis And Prostate Cancer Specific Mortality Following Radiotherapy. *Int J Radiat Oncol Biol Phys.* 2008 Jan 1;70(1):59-66. Epub 2007 Oct 4.
 38. Morgan PB, Hanlon AL, Horwitz EM, **Buyyounouski MK**, Uzzo RG, Pollack A. Timing of biochemical failure and distant metastatic disease for low-, intermediate-, and high-risk prostate cancer after radiotherapy. *Cancer.* 2007 Jul 1;110(1):68-80.
 39. D'Ambrosio DJ, Glass J, Cohen R, Konski A, **Buyyounouski MK**, Feigenberg SJ. Unexpected dementia following prophylactic cranial irradiation for small cell lung cancer: case report. *J Neurooncol.* 2007 Oct;85(1):77-9. Epub 2007 Apr 20.
 40. Eade TN, Al-Saleem T, Horwitz EM, **Buyyounouski MK**, Chen DYT, Pollack A. Role of radiotherapy in ductal (endometrioid) carcinoma of the prostate. *Cancer.* 2007 May 15;109(10):2011-5.
 41. Eade TN, Hanlon AL, Horwitz EM, **Buyyounouski MK**, Hanks GE, Pollack A. What dose of external-beam radiation is high enough for prostate cancer? *Int J Radiat Oncol Biol Phys.* 2007 Jul 1;68(3):682-9. Epub 2007 Mar 29.
 42. D'Ambrosio DJ, Hanlon A, Al-Saleem T, Feigenberg S, Horwitz E, Pollack A, **Buyyounouski MK***. The Proportion of Prostate Biopsy Tissue with Gleason Pattern 4 Or 5 Predicts for Biochemical And Clinical Outcomes After Radiotherapy For Prostate Cancer. *Int J Radiat Oncol Biol Phys.* 2007 Mar 15;67(4):1082-7. Epub 2007 Jan 22.
 43. Morgan PB, Hanlon AL, Horwitz EM, **Buyyounouski MK**, Uzzo RG, Pollack A. Radiation dose and late failures in prostate cancer. *Int J Radiat Oncol Biol Phys.* 2007 Mar 15;67(4):1074-81. Epub 2006 Dec 29.
 44. Alcantara P, Hanlon A, **Buyyounouski MK**, Horwitz EM, Pollack A. Prostate-specific antigen nadir within 12 months of prostate cancer radiotherapy predicts metastasis and death. *Cancer* 2006, 109(1):41-47.
 45. Price RA, Hannoun-Levi JM, Horwitz EM, **Buyyounouski M**, Ruth KJ, Ma C-M, Pollack. Impact of pelvic nodal irradiation with intensity-modulated radiotherapy on treatment of prostate cancer. *Int J Radiat Oncol Biol Phys.* 2006 Oct 1;66(2):583-92.
 46. Pollack A, Hanlon AL, Horwitz EM, Feigenberg SJ, Konski AA, Movsas B, Greenberg RE, Uzzo RG, Ma C-M C, McNeeley SW, **Buyyounouski MK**, Price RA. Dosimetry and preliminary acute toxicity in the first 100 men treated for prostate cancer on a randomized hypofractionation dose escalation trial. *Int J Radiat Oncol Biol Phys.* 2006 Feb 1;64(2):518-26. Epub 2005 Oct 19.
 47. **Buyyounouski MK**, Hanlon AL, Eisenberg DF, Horwitz EM, Feigenberg SJ, Uzzo RG, Pollack A. Defining biochemical failure after radiotherapy with and without androgen deprivation for prostate cancer. *Int J Radiat Oncol Biol Phys* 2005, 63(5):1455-62. Epub 2005 Sep 19.
 48. **Buyyounouski MK**, Hanlon AL, Horwitz EM, Uzzo RG, Pollack A. Biochemical failure and the temporal kinetics

- of prostate-specific antigen after radiation therapy with androgen deprivation. *Int J Radiat Oncol Biol Phys.* 2005 Apr 1;61(5):1291-8.
49. **Buyyounouski MK**, Klump WJ, Konski A, Wu H, Adler LP. FDG PET imaging of signet-ring cell adenocarcinoma of the stomach. *Clin Nucl Med.* 2005 Feb;30(2):118-9.
 50. **Buyyounouski MK**, Horwitz EM, Uzzo RG, Price RA, McNeeley SW, Azizi D, Hanlon AL, Milestone BN, Pollack A. The radiation doses to erectile tissues defined with magnetic resonance imaging after intensity-modulated radiation therapy or iodine-125 brachytherapy. *Int J Radiat Oncol Biol Phys.* 2004 Aug 1;59(5):1383-91.
 51. **Buyyounouski MK**, Horwitz EM, Uzzo RG, Price RA, Hanlon AL, Pollack, A. Intensity-modulated radiotherapy with MRI simulation to reduce doses received by erectile tissue during prostate cancer treatment. *Int J Radiat Oncol Biol Phys.* 2004 Mar 1;58(3):743-9.
 52. **Buyyounouski MK**, Horwitz EM, Hanlon AL, Uzzo RG, Hanks GE, and Pollack, A, Positive Prostate Biopsy Laterality and Implications for Staging. *Urology* 2003; 62:298- 303.
 53. Kaminski JM, Nguyen K, **Buyyounouski M**, Pollack A. Prostate cancer gene therapy and the role of radiation. *Cancer Treat Rev.* 2002 Feb;28(1):49-64. [Review]
 54. Rubin MA, **Buyyounouski M**, Baglella E, Sharir S., Neugut A, Benson MC, Katz AE, Olsson CA, Ennis R. Microvessel density in prostate cancer: lack of correlation with tumor grade, pathologic stage, and clinical outcome. *Urology.* 1999 Mar;53(3):542-7.
 55. Hogenboom DL, Kargel JS, Consolmagno CJ, Holden TC, Lee L, **Buyyounouski M**. The ammonia-water system and the chemical differentiation of icy satellites. *Icarus* 1997 Jul;128(1):171-180.

Book Chapters, Letters, and Editorials

1. Pollack A, Li T, **Buyyounouski MK**, Horwitz E, Price R, Stoyanova R, Feigenberg S, Konski A, Ma C. Hypofractionation For Prostate Cancer: The Fox Chase/University of Miami Experience. In *Hypofractionation 2011*. A Pollack and M Ahmed (eds.), LumiText Publishing, Elliot City, MD. 2011. [Book Chapter]
2. Loehrer P, Jayaram N, Dash A, **Buyyounouski MK**, Skarecky D. Testicular Cancer. In: *Cancer Management: A Multidisciplinary Approach*, 14 Ed. R Pazdur, L Wagman, K Cammphausen, W Hoskins (eds.), CMPMedica, Norwalk, CT. [Book Chapter]
3. **Buyyounouski MK**. Androgen Deprivation Therapy in High-risk Prostate Cancer. *Oncology (Williston Park).* 2010 Aug;24(9):806, 809. [Editorial]
4. **Buyyounouski MK**. Radiotherapy: PSA nadir predicts long-term mortality. *Nat Rev Clin Oncol.* 2010 Apr;7(4):188-90. [Editorial]
5. Loehrer P, Jayaram N, Dash A, **Buyyounouski MK**, Skarecky D. Testicular Cancer. In: *Cancer Management: A Multidisciplinary Approach*, 13 Ed. R Pazdur, L Wagman, K Cammphausen, W Hoskins (eds.), CMPMedica, Norwalk, CT, In Press. [Book Chapter]
6. **Buyyounouski MK**. Surveillance for stage I seminoma: better the devil you know than the devil you don't? *Oncology (Williston Park).* 2009 Aug;23(9):762, 764. [Invited editorial]
7. Williams SG, Pickles T, **Buyyounouski MK**. Androgen Deprivation Therapy and Prostate Cancer Duration. *J Clin Oncol.* 2009 Nov 2. [Epub ahead of print] [Letter to the Editor]
8. Loehrer P, Jayaram N, Dash A, **Buyyounouski MK**, Skarecky D. Testicular Cancer. In: *Cancer Management: A Multidisciplinary Approach*, 12 Ed. R Pazdur, L Wagman, K Cammphausen, W Hoskins (eds.), CMPMedica, Norwalk, CT, 2009. [Book Chapter]
9. **Buyyounouski MK**, Horwitz EM. MRI Target Delineation in Prostate Cancer. In *IGRT: A Clinical Perspective*. AJ Mundt et al. (Eds) In Preparation. [Book Chapter]

10. Pollack A, Eade TM, Horwitz EM, **Buyyounouski MK**, Hanks GE. In reply to drs. Schultz and kagan. *Int J Radiat Oncol Biol Phys*. 2008 Jul 15;71(4):1288-9. [Letter to the Editor]
11. Pollack A, Eade TN, Hanlon AL, Horwitz EM, **Buyyounouski MK**, Hanks GE. In Reply to Drs. Cheung and Schulz and Kagan. *Int J Radiat Oncol Biol Phys*. 2008 Feb 1;70(2):645-646. [Letter to the Editor]
12. **Buyyounouski MK**. Comment on influence of local tumor control as assessed by post-treatment prostate biopsies after external beam radiotherapy for prostate cancer on distant metastases and cancer related mortality. *J Urol*. 2008 Feb 18. [Invited Editorial]
13. Loehrer P, Ahlering T, **Buyyounouski MK**. Testicular Cancer. In: *Cancer Management: A Multidisciplinary Approach*, 11th Ed. R Pazdur, L Coia, L Wagman, W Hoskins (eds.), PRR Treatment Handbook. PRR, Huntington, NY, 2008. [Book Chapter]
14. **Buyyounouski MK**, Horwitz, EH, Pollack A. Prostate. In: *Handbook of Radiation Oncology*. BG Haffty, LD Wilson (eds.), Jones and Bartlett, 2008. [Book Chapter]
15. Loehrer P, Ahlering T, **Buyyounouski MK**. Testicular Cancer. In: *Cancer Management: A Multidisciplinary Approach*, 10th Ed. R Pazdur, L Coia, L Wagman, W Hoskins (eds.), PRR Treatment Handbook. PRR, Huntington, NY, 2007. [Book Chapter]
16. **Buyyounouski MK**, Horwitz EM, Price Jr RA, Feigenberg SJ and Pollack A. Prostate IMRT. In *IMRT Handbook: Concepts & Clinical Applications*. Bortfeld T, Rupert Schmidt-Ullrich R, de Neve W, Wazer DE (Eds). Springer-Verlag Heidelberg, Germany, 2006. [Book Chapter]
17. **Buyyounouski MK** and Pollack A. External Beam Radiation Therapy for Prostate Cancer. In *Atlas of the Prostate*; 3rd Ed. Current Medicine LLC, Philadelphia, USA, 2006. [Book Chapter]
18. **Buyyounouski MK**, Hanlon AL, Price RA, Horwitz EM, Feigenberg SJ, Pollack A. In regard to Selek et al. erectile dysfunction and radiation dose to penile base structures: a lack of correlation. *IJROBP* 2004;59:1039-1046. *Int J Radiat Oncol Biol Phys*. 2004 Dec 1;60(5):1664-5; author reply 1666. [Letter to the Editor]
19. **Buyyounouski MK**, Horwitz EM, Hanlon AL, Uzzo RG, Pollack A. Re: improved clinical staging system combining biopsy laterality and TNM stage for men with T1c and T2 prostate cancer: results from the search database. *J Urol*. 2004 Mar;171(3):1246-7; author reply 1247. [Letter to the Editor]